



Sotrastaurin

Catalog No: tcsc0090

Available Sizes
Size: 5mg
Size: 10mg
Size: 50mg
Specifications
CAS No: 425637-18-9
Formula: C ₂₅ H ₂₂ N ₆ O ₂
Pathway: TGF-beta/Smad;Epigenetics
Target: PKC;PKC
Purity / Grade: >98%
Solubility: 10 mM in DMSO
Alternative Names: AEB071
Observed Molecular Weight: 438.48

Product Description





Sotrastaurin is a potent pan-**PKC** inhibitor, with $\mathbf{K_i}$ s of 0.22 nM, 0.64nM, 0.95 nM, 1.8 nM, 2.1 nM and 3.2 nM for PKC θ , PKC θ

IC50 & Target: IC50: 0.22 nM (PKCθ), 0.64 nM (PKCβ), 0.95 nM (PKCα), 1.8 nM (PKCη), 2.1 nM (PKCδ), 3.2 nM (PKCε) $^{[1]}$

In Vitro: In cell-free kinase assays Sotrastaurin (AEB071) inhibits PKC, with K_i values in the subnanomolar to low nanomolar range. When Sotrastaurin is tested on a selected panel of kinases, the only enzyme on which Sotrastaurin displays an IC_{50} value below 1 μ M is glycogen synthase kinase 3 $\beta^{[1]}$. Sotrastaurin (AEB071) inhibits p-MARCKS, a PKC substrate, and pS6 in all the cell lines, independently of the mutational status. There is a slight inhibition of pERK at lower doses also in the GNA11 mutant cells, but not in the WT cells at any concentrations. This is consistent with previous reports indicating that Sotrastaurin inhibits ERK1/2 phosphorylation in GNAQ mutant cell lines^[2].

In Vivo: The combination therapy results in a significantly enhanced reduction in tumor volume when compared to either Sotrastaurin (AEB071) or BYL719 alone (p=0.049 vs. BYL719 and p=0.022 vs. Sotrastaurin at day 26). There is even a greater effect when compared to vehicle control (p=0.016)^[2]. Sotrastaurin (STN) treatment of liver donors and orthotopic liver transplantation (OLT) recipients (Gr.I) or of OLT recipients alone (Gr.II) prolongs animal survival, as 9 out of 10 rats in Gr. I, and 6 out of 6 rats in Gr.II survive >14 days. In contrast, only 4 out of 10 control OLT recipients remain alive at day 14 (p[3].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!